Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Merck Serono Pens Diagnostics Deal
by Marc S. Reisch
July 22, 2013
| A version of this story appeared in
Volume 91, Issue 29
Merck Serono and instrument maker Life Technologies have signed a nonexclusive agreement to develop diagnostic tests to complement Merck’s drugs. The two intend to focus on oncology initially, but they expect to broaden their efforts to cover a range of therapeutic areas. They also plan to work together to win regulatory approval for new drugs and companion diagnostics. Life and Bristol-Myers Squibb reached a similar deal last year. In April, Thermo Fisher Scientific agreed to buy Life for $15.8 billion. Completion of that deal is expected in early 2014.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X